Lebrikizumab — Drug Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

4 Recruiting

4 Completed trials

5 Sponsors

16 Countries

Phase III

Phase IV

Phase III: 8 Phase II: 1 Phase IV: 2

Oversight events:

1 serious breach 1 corrective measure across 2 trials

View oversight register →

Sponsors using this IMP

Almirall S.A. 4 Eli Lilly & Co. 4 Charite Universitaetsmedizin Berlin KöR 1 Region Oestergoetland 1 University Of Michigan 1

All trials

11 total

An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and no… Pending

2024-519811-32-00 Phase IV 1 country Region Oestergoetland
ADfind Pending

2025-521833-97-00 Phase IV 1 country University Of Michigan
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized s… Pending

2025-524435-39-00 Phase II 1 country Charite Universitaetsmedizin Berlin KöR
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Ato… Recruiting

2022-501478-21-00 Phase III 5 countries Eli Lilly & Co.
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting

2025-522403-17-00 Phase III 5 countries Almirall S.A.
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO… Recruiting

2023-508760-29-00 Phase III 11 countries Eli Lilly & Co.
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis Recruiting

2023-508817-18-00 Phase III 3 countries Eli Lilly & Co.
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Ended

2023-508235-31-00 Phase III 6 countries Almirall S.A.
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-S… Ended

2023-505558-16-00 Phase III 2 countries Almirall S.A.
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Ended

2022-501476-25-00 Phase III 5 countries Eli Lilly & Co.
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera… Ended

2022-502575-30-00 Phase III 2 countries Almirall S.A.

Showing 1–11 of 11 trials

← All drugs A–Z